Table 3 Mortality of all encephalopathic critically ill oncological patients
Variable | All patients | Survived | Dead | p value |
|---|---|---|---|---|
(n = 317) | (n = 193) | (n = 124) | ||
Age | 60.2 ± 14.6, 62 (18–89) | 58.9 ± 15.5, 62 (18–87) | 61.1 ± 14, 62 (18, 89) | 0.34 |
Gender (male) | 59.3% | 56.5% | 61.1% | 0.407 |
Type of malignancy | 0.609 | |||
Hematological | 61.8% | 58.9% | 63.7% | 0.385 |
Solid tumor | 38.2% | 41.1% | 36.3% | |
Metastatic disease | 72.7% | 92.7% | 74.2% | 0.035 |
Active disease (no remission) | 86.8% | 82.3% | 89.6% | 0.059 |
Stem cell transplant (yes) | 31.6% | 21.8% | 18.1% | 0.214 |
Co-morbidity index ≥ 5 | 68.5% | 66.1% | 69.9% | 0.475 |
Chemotherapy within 10 days | 24.3% | 28.2% | 21.8% | 0.190 |
CNS malignancy involvement* | 26.5% | 33.9% | 21.8% | 0.017 |
Medical history of seizure disorder | 10.4% | 16.1% | 10.9% | 0.008 |
Medical service | 89.3% | 83.0% | 94.8% | 0.006 |
Variables during ICU stay | ||||
SOFA on admission** | 8.5 ± 3.7, 8 (0–19) | 7.2 ± 3.3, 7 (0–16) | 9.3 ± 3.8, 9 (2–19) | < 0.0001 |
SOFA at time of EEG # | 9.9 ± 4.0, 10 (3–22) | 8.2 ± 3.7, 7 (3–21) | 11.1 ± 3.7, 11 (3–22) | < 0.0001 |
GCS at time of EEG## (median) | 7 (3–12) | 8 (3–12) | 7 (3–12) | 0.001 |
Vasopressors (yes) | 56.5% | 35.5% | 69.9% | < 0.0001 |
Acute renal failure (yes) | 52.4% | 31.5% | 65.8% | < 0.0001 |
Mechanical Ventilation (yes) | 79.5% | 66.9% | 87.6% | < 0.0001 |
Use of sedatives (yes) | 49.8% | 44.4% | 53.4% | 0.117 |
Cardiac arrest during ICU stay | 13.3% | 3.2% | 19.7% | < 0.0001 |